Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
39 hedge funds and large institutions have $65M invested in Cymabay Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 4 closing their positions.
967% more call options, than puts
Call options by funds: $32K | Put options by funds: $3K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
43% more capital invested
Capital invested by funds: $45.5M → $65M (+$19.5M)
15% more funds holding
Funds holding: 34 → 39 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.65M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$814K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$724K |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$639K |
| 5 |
IHM
Iguana Healthcare Management
New York
|
+$447K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.5M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$518K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$294K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$129K |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$105K |
CBAY Hedge Fund Activity: Q2 2017 in Review
39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2017, worth a combined $65M — up 43% from $45.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CBAY positions and 4 closed out — a net gain of 5 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.65M. The largest seller was Boxer Capital, cutting an estimated $1.5M.
- 39 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2017, up from 34 in Q1 2017.
- Funds reported $65M of Cymabay Therapeutics stock for Q2 2017, up 43% quarter-over-quarter.
- 9 funds opened new Cymabay Therapeutics positions in Q2 2017 and 4 closed out, a net change of +5 holders.
- The largest Cymabay Therapeutics buyer in Q2 2017 was Millennium Management, an estimated $1.65M added.
- The largest Cymabay Therapeutics seller in Q2 2017 was Boxer Capital, an estimated $1.5M sold.
Based on aggregated 13F filings for Q2 2017.